SI9420052B - Kristalni brezvodni mikofenolatni mofetil in njegova intravenozna formulacija - Google Patents
Kristalni brezvodni mikofenolatni mofetil in njegova intravenozna formulacija Download PDFInfo
- Publication number
- SI9420052B SI9420052B SI9420052A SI9420052A SI9420052B SI 9420052 B SI9420052 B SI 9420052B SI 9420052 A SI9420052 A SI 9420052A SI 9420052 A SI9420052 A SI 9420052A SI 9420052 B SI9420052 B SI 9420052B
- Authority
- SI
- Slovenia
- Prior art keywords
- compound
- salt
- temperature
- crystalline anhydrous
- range
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (14)
- A PATENTNI ZAHTEVKI 1. Kristalna brezvodna spojina s formulokjer je spojina kompleksirana kot sol z anionom, izbranim iz skupine, ki jo sestavljajo klorid, sulfat, fosfat in acetat.
- 2. Spojina po zahtevku 1, označena s tem, daje anion klorid.
- 3. Kristalna brezvodna spojina po zahtevku 2, označena s tem, da ima tališče od 145°C do 155°C.
- 4. Kristalni brezvodni 2-(4-morfolino)etil- E-6-(l,3-dihidro- 4-hidroksi-6-metoksi-7-metil-3-okso-5-izobenzofuranil)-4-metil-4-heksenoat hidroklorid po zahtevku 1.
- 5. Sestavek, primeren za pripravo vodne intravenozne formulacije, označen s tem, da obsega spojino s formulokjer je spojina kompleksirana kot sol z anionom, izbranim iz skupine, ki jo sestavljajo klorid, sulfat, fosfat ter acetat in je navedena sol v kristalni brezvodni obliki, in farmacevtsko sprejemljive nosilce.
- 6. Sestavek po zahtevku 5, označen s tem, da je edini farmacevtsko sprejemljivi nosilec polisorbat 80. 2
- 7. Sestavek po zahtevku 5, označen s tem, da sta farmacevtsko sprejemljiva nosilca polisorbat 80 in citronska kislina.
- 8. Postopek za pripravo sestavka, primernega za pripravo intravenozne formulacije, ki obsega spojino s formulokjer je spojina kompleksirana z anionom, izbranim iz skupine, ki jo sestavljajo klorid, sulfat, fosfat ter acetat in je navedena sol v kristalni brezvodni obliki, in farmacevtsko sprejemljive nosilce, označen s tem, da obsega: a) združevanje navedene spojine in farmacevtsko sprejemljivih nosilcev, da dobimo polnilno raztopino, pri čemer je pH navedene polnilne raztopine naravnan na 3,2 do 3,6, b) polnjenje navedene polnilne raztopine v fiole in c) liofiliziranje navedenih napolnjenih fiol, da dobimo navedeni sestavek.
- 9. Postopek po zahtevku 8, označen s tem, da liofilizacijska stopnja obsega: a) zniževanje temperature v območju od 25°C do -40°C; b) zniževanje tlaka na 13,3 Pa; c) zviševanje temperature v območju od -40°C do 70°C; in d) zniževanje temperature v območju od 70°C do 25°C.
- 10. Postopek po zahtevku 8, označen s tem, da navedena liofilizacijska stopnja 3 obsega: a) zniževanje temperature v območju od 25°C do -10°C pri hitrosti spreminjanja -0,25°C/min; b) vzdrževanje temperature pri -10°C 2 uri in 30 minut; c) zniževanje temperature v območju od -10°C do -40°C pri hitrosti spreminjanja ~0,25°C/min; d) zniževanje tlaka na 13,3 Pa; e) zviševanje temperature v območju od -40°C do -16°C pri hitrosti spreminjanja 0,05°C/min; f) zviševanje temperature v območju od -16°C do 70°C pri hitrosti spreminjanja 0,20°C/min ±0,1°C; in g) zniževanje temperature v območju od 70°C do 25°C.
- 11. Uporaba spojine s formulokjer je spojina kompleksirana kot sol z anionom, izbranim iz skupine, ki jo sestavljajo klorid, sulfat, fosfat ter acetat in je navedena sol v njeni kristalni brezvodni obliki, za pripravo zdravila za zdravljenje zavračanja transplantacij, ki vključujejo zlasti zavračanje srčnih transplantacij, zavračanje pankreasnih transplantacij in zavračanje renalnih transplantacij ter za zdravljenje avtoimunskih motenj, psoriaze, vnetnih bolezni, ki vključujejo zlasti revmatoidni artritis, diabetesa, tumorjev in virusnih bolezni.
- 12. Uporaba sestavka po zahtevkih 5 - 7 za pripravo intravenozne formulacije, ki nadalje obsega tekoč medij, pri čemer združimo tekoč medij in sestavek pred dajanjem.
- 13. Postopek za pripravo intravenozne formulacije, označen s tem, da obsega mešanje a) spojine s formulokjer je spojina kompleksirana kot sol z anionom, izbranim iz skupine, ki jo sestavljajo klorid, sulfat, fosfat ter acetat in je navedena sol v njeni kristalni brezvodni obliki, b) farmacevtsko sprejemljivih nosilcev in c) tekočega medija.
- 14. Komplet, uporaben za pripravo intravenozne formulacije, označen s tem, da obsega a) sestavek, ki obsega spojino s formulo 5·kjer je spojina kompleksirana kot sol z anionom, izbranim iz skupine, ki jo sestavljajo klorid, sulfat, fosfat ter acetat in je navedena sol v kristalni brezvodni obliki, in farmacevtsko sprejemljive nosilce in b) ustrezno količino tekočega medija.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12184193A | 1993-09-15 | 1993-09-15 | |
PCT/US1994/010142 WO1995007902A1 (en) | 1993-09-15 | 1994-09-12 | Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9420052A SI9420052A (en) | 1996-12-31 |
SI9420052B true SI9420052B (sl) | 2004-02-29 |
Family
ID=22399119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9420052A SI9420052B (sl) | 1993-09-15 | 1994-09-12 | Kristalni brezvodni mikofenolatni mofetil in njegova intravenozna formulacija |
Country Status (32)
Country | Link |
---|---|
US (2) | US5543408A (sl) |
EP (1) | EP0724581B1 (sl) |
JP (1) | JP3411038B2 (sl) |
KR (1) | KR100349772B1 (sl) |
CN (1) | CN1060770C (sl) |
AT (1) | ATE173475T1 (sl) |
AU (1) | AU677435B2 (sl) |
BR (1) | BR9407469A (sl) |
CA (1) | CA2171836C (sl) |
CZ (1) | CZ292423B6 (sl) |
DE (1) | DE69414720T2 (sl) |
DK (1) | DK0724581T3 (sl) |
ES (1) | ES2123831T3 (sl) |
FI (1) | FI119639B (sl) |
HK (1) | HK1012624A1 (sl) |
HU (1) | HU217300B (sl) |
IL (1) | IL110970A (sl) |
LT (1) | LT4052B (sl) |
LV (1) | LV11326B (sl) |
MX (1) | MXPA94007099A (sl) |
NO (1) | NO314727B1 (sl) |
NZ (1) | NZ273801A (sl) |
PH (1) | PH30685A (sl) |
PL (1) | PL178522B1 (sl) |
RO (2) | RO118075B1 (sl) |
RU (1) | RU2132849C1 (sl) |
SG (1) | SG55006A1 (sl) |
SI (1) | SI9420052B (sl) |
TW (1) | TW370527B (sl) |
UA (1) | UA49797C2 (sl) |
WO (1) | WO1995007902A1 (sl) |
ZA (1) | ZA947088B (sl) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
IN188985B (sl) * | 1998-12-09 | 2002-11-30 | Biocon Ltd | |
GB0301259D0 (en) | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
US20050187170A1 (en) * | 2003-06-16 | 2005-08-25 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors |
ES2308226T3 (es) * | 2003-09-11 | 2008-12-01 | Sandoz Ag | Proceso para la produccion de micofenolato mofetil. |
EP1740564A2 (en) * | 2004-04-26 | 2007-01-10 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Process for preparation of mycophenolic acid and ester derivatives thereof |
MXPA06005658A (es) * | 2004-04-27 | 2007-04-10 | Teva Gyogyszergyar Zartkoruen | Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico. |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
CN101052631A (zh) * | 2004-07-20 | 2007-10-10 | 特瓦药厂私人有限公司 | 结晶霉酚酸钠 |
CN100383520C (zh) * | 2004-09-20 | 2008-04-23 | 复旦大学 | 一种测定人血浆中霉酚酸及其代谢物的方法 |
US20060235009A1 (en) * | 2005-02-08 | 2006-10-19 | Richard Glickman | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors |
US20060235070A1 (en) * | 2005-02-08 | 2006-10-19 | Hayden Michael R | Compositions and methods for treating vascular, autoimmune, and inflammatory diseases |
US20080281111A1 (en) * | 2005-04-26 | 2008-11-13 | Sandor Molnar | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid |
EP2032521B1 (en) | 2006-06-27 | 2009-10-28 | Sandoz AG | New method for salt preparation |
CN101953807A (zh) * | 2010-10-09 | 2011-01-26 | 山西普德药业有限公司 | 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法 |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
PT2970101T (pt) | 2013-03-14 | 2018-10-04 | Alkermes Pharma Ireland Ltd | Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças |
US9168246B2 (en) | 2013-06-27 | 2015-10-27 | Veloxis Pharmaceutical A/S | Regimen for suppressing organ rejection |
NZ723269A (en) | 2014-02-24 | 2017-04-28 | Alkermes Pharma Ireland Ltd | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US11918684B2 (en) | 2017-03-13 | 2024-03-05 | Liqmeds Worldwide Limited | Pharmaceutical composition of oral suspension of immunosuppressive agents |
CA3212370A1 (en) | 2021-03-03 | 2022-09-09 | Sana Biotechnology, Inc. | Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4328213A (en) * | 1979-11-28 | 1982-05-04 | Schering Corporation | Stable injectable labetalol formulation |
US4478829A (en) * | 1983-04-28 | 1984-10-23 | Armour Pharmaceutical Company | Pharmaceutical preparation containing purified fibronectin |
US4753935A (en) | 1987-01-30 | 1988-06-28 | Syntex (U.S.A.) Inc. | Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions |
-
1994
- 1994-09-12 JP JP50925595A patent/JP3411038B2/ja not_active Expired - Lifetime
- 1994-09-12 DE DE69414720T patent/DE69414720T2/de not_active Expired - Lifetime
- 1994-09-12 CZ CZ1996788A patent/CZ292423B6/cs not_active IP Right Cessation
- 1994-09-12 RO RO96-00567A patent/RO118075B1/ro unknown
- 1994-09-12 SG SG1996001679A patent/SG55006A1/en unknown
- 1994-09-12 ES ES94928054T patent/ES2123831T3/es not_active Expired - Lifetime
- 1994-09-12 SI SI9420052A patent/SI9420052B/sl unknown
- 1994-09-12 BR BR9407469A patent/BR9407469A/pt not_active Application Discontinuation
- 1994-09-12 HU HU9600652A patent/HU217300B/hu unknown
- 1994-09-12 WO PCT/US1994/010142 patent/WO1995007902A1/en active IP Right Grant
- 1994-09-12 NZ NZ273801A patent/NZ273801A/en not_active IP Right Cessation
- 1994-09-12 CN CN94193413A patent/CN1060770C/zh not_active Expired - Lifetime
- 1994-09-12 AT AT94928054T patent/ATE173475T1/de active
- 1994-09-12 PL PL94313480A patent/PL178522B1/pl unknown
- 1994-09-12 AU AU77238/94A patent/AU677435B2/en not_active Expired
- 1994-09-12 RU RU96107396A patent/RU2132849C1/ru active
- 1994-09-12 CA CA002171836A patent/CA2171836C/en not_active Expired - Lifetime
- 1994-09-12 DK DK94928054T patent/DK0724581T3/da active
- 1994-09-12 KR KR1019960701354A patent/KR100349772B1/ko not_active IP Right Cessation
- 1994-09-12 EP EP94928054A patent/EP0724581B1/en not_active Expired - Lifetime
- 1994-09-12 RO ROA200201154A patent/RO118427B1/ro unknown
- 1994-09-14 TW TW083108484A patent/TW370527B/zh not_active IP Right Cessation
- 1994-09-14 IL IL11097094A patent/IL110970A/en not_active IP Right Cessation
- 1994-09-14 ZA ZA947088A patent/ZA947088B/xx unknown
- 1994-09-14 PH PH48985A patent/PH30685A/en unknown
- 1994-12-05 US US08/349,236 patent/US5543408A/en not_active Expired - Lifetime
- 1994-12-09 UA UA96031026A patent/UA49797C2/uk unknown
-
1995
- 1995-06-02 US US08/459,991 patent/US5545637A/en not_active Expired - Lifetime
-
1996
- 1996-03-13 FI FI961169A patent/FI119639B/fi not_active IP Right Cessation
- 1996-03-15 NO NO19961075A patent/NO314727B1/no not_active IP Right Cessation
- 1996-03-15 LT LT96-028A patent/LT4052B/lt not_active IP Right Cessation
- 1996-03-15 LV LVP-96-85A patent/LV11326B/en unknown
-
1997
- 1997-12-05 MX MXPA94007099A patent/MXPA94007099A/es active IP Right Grant
-
1998
- 1998-12-17 HK HK98113833A patent/HK1012624A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9420052B (sl) | Kristalni brezvodni mikofenolatni mofetil in njegova intravenozna formulacija | |
EP0602586B1 (en) | Stable pharmaceutical composition of fumagillol derivatives | |
RU96107396A (ru) | Кристаллический безводный микофенолят мофетила и состав для внутривенных инъекций из него | |
ATE378341T1 (de) | Verfahren zur formulierung antibiotischer verbindungen | |
FI68359C (fi) | Foerfarande foer framstaellning av en stabil prostacyklinkomposition foer terapeutiskt anvaendning | |
EP0386668B1 (en) | Lyophilized dihydrochloride of 7-[alpha-(2-aminothiazol-4-yl)-alpha-(Z)-methoxyiminoacetamido]-3-[(1-methyl-1-pyrrolidinium)-methyl]-3-cephem-4-carboxylate | |
DK535384D0 (da) | 1,3-dioxan-4-yl-alken- og alkansyrer, fremgangsmaader til fremstilling heraf og midler med indhold heraf | |
US3767803A (en) | Stable aqueous pyritinol solutions | |
DK0497978T3 (da) | Cephalosporinforbindelser og fremstilling heraf. | |
JPH0317094A (ja) | レベカマイシン類似体の安定な溶液およびその製造 | |
CA1308358C (en) | Antibacterial lyophilized preparation | |
ATE34739T1 (de) | Neue 2-pyridin-thiol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate. | |
DK162286C (da) | Penemderivat, farmaceutisk praeparat indeholdende dette, anvendelse af derivatet samt fremgangsmaader til fremstilling deraf | |
DE3270406D1 (en) | Amidines, process for their preparation, pharmaceutical compounds containing them and their use | |
ES8304577A1 (es) | "procedimiento para la preparacion de nuevas cefalosporinas". | |
JPS6337115B2 (sl) | ||
GB1089587A (en) | Novel benzdiaz(1,4)epine derivatives and a process for the manufacture thereof | |
JPH04145025A (ja) | ブレオマイシン類の安定な水溶液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date |